Panel firm offers speedy trend analysis

Share this article:
All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
The service, Snapshot, can generate sample sizes in the hundreds across six countries, according to a release. For example, within hours of the FDA's decision to severely restrict use of GlaxoSmithKline diabetes pill Avandia, Snapshot closed a survey of 100 UK diabetes specialists and endocrinologists, with 63% saying the news would encourage their use of a DPP 4 inhibitor/GLP 1 mimetic, 12% saying they would initiate insulin earlier, and 13% saying they would not change Rx habits.
Release of FDA ad-com briefing documents for weight-loss candidate Qnexa prompted a Snapshot survey of 730 US PCPs, with 82% saying they would recommend approval. In a follow-up survey of 398 PCPs after the ad-com voted 10-6 against approval, 68% said they would have recommended approval.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?